ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Epizyme Inc

Epizyme Inc (EPZM)

1.47
0.00
(0.00%)
종가: 20 11월 6:00AM
1.47
0.00
( 0.00% )
시간외 거래: -

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
1.47
매수가
1.61
매도가
1.40
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
전일 종가
1.47
개장가
-
최근 거래 시간
마지막 거래 시간
-
평균 볼륨(3m)
-
재정 규모
-
VWAP
-

EPZM 최신 뉴스

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the...

Ipsen to acquire Epizyme, expanding its portfolio in oncology

Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen’s growing oncology presence and leverage its...

Ipsen acquiert Epizyme et étend son portefeuille en Oncologie

Actif principal Tazverik® (tazemetostat), un inhibiteur de l’EZH2a, premier de sa catégorie de produits approuvé aux États-Unis Renforcement de la présence d’Ipsen en oncologie tout en...

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Updated Activity Data from Phase 1b Portion of the Study Shows Continued Improvement in Both Objective and Complete Response Rates Update Includes Response Data for Sub-Group of Patients Who Are...

Epizyme To Participate in H.C. Wainwright Global Investment Conference

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets...

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the...

Epizyme Announces Date of First Quarter 2022 Financial Results

Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets...

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets...

 Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update

Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme’s Phase 1b/3 Confirmatory Study of Tazemetostat in...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.2671
(64.17%)
47.5M
DBGIDigital Brands Group Inc
US$ 0.158
(35.51%)
42.15M
HOTHHoth Therapeutics Inc
US$ 1.09
(33.25%)
10.8M
JXJTJX Luxventure Ltd
US$ 1.64
(26.15%)
729
ZEOZeo Energy Corporation
US$ 1.5201
(25.63%)
4.64k
POWLPowell Industries Inc
US$ 277.00
(-11.33%)
181.08k
TRNRInteractive Strength Inc
US$ 3.61
(-8.38%)
118.8k
PRFXPainReform Ltd
US$ 1.29
(-7.86%)
1.59M
APLMApollomics Inc
US$ 0.1517
(-7.67%)
975.88k
SYRSSyros Pharmaceuticals Inc
US$ 0.2557
(-7.62%)
1.89M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.267
(64.11%)
47.59M
DBGIDigital Brands Group Inc
US$ 0.158
(35.51%)
42.16M
HOTHHoth Therapeutics Inc
US$ 1.09
(33.25%)
10.8M
ELABElevai Labs Inc
US$ 0.02095
(-1.64%)
6.66M
SMXSMX Security Matters Public Company
US$ 0.2749
(13.13%)
5.97M

EPZM Discussion

게시물 보기
Enterprising Investor Enterprising Investor 2 년 전
Expiration of the Offer (8/12/22)

The Offer and all withdrawal rights thereunder expired at 11:59 p.m., Eastern Time, on August 11, 2022 (the “Expiration Time”). Computershare Trust Company, N.A., in its capacity as depositary and paying agent for the Offer (the “Depositary and Paying Agent”), has advised the Parent and the Purchaser that, as of the Expiration Time, a total of 124,185,125 Shares (excluding Shares with respect to which notices of guaranteed delivery were delivered) were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74% of the Shares outstanding as of the Expiration Time. In addition, the Depositary and Paying Agent has advised the Parent and the Purchaser that, as of the Expiration Time, notices of guaranteed delivery had been delivered with respect to 9,299,176 additional Shares, representing approximately 6% of the outstanding Shares as of the Expiration Time.

As of the Expiration Time, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition, and all other conditions to the Offer were satisfied or waived. Accordingly, the Purchaser has accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer and will promptly pay for all such Shares in accordance with the terms of the Offer.

As a result of its acceptance for payment of the Shares validly tendered and not validly withdrawn pursuant to the Offer and in accordance with Section 251(h) of the DGCL, the Purchaser owns at least the percentage of Shares that would be required to adopt the Merger Agreement without a vote of the stockholders of the Company.

Accordingly, the Parent and the Purchaser expect to complete the acquisition of the Company on August 12, 2022 by consummating the Merger pursuant to the Merger Agreement without a vote of the Company’s stockholders in accordance with Section 251(h) of the DGCL. At the Effective Time: (i) the Purchaser shall be merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned indirect subsidiary of Parent, and (ii) each remaining outstanding Share not accepted for payment in the Offer (other than the Excluded Shares) that are issued and outstanding immediately prior to the Effective Time shall be cancelled, shall cease to exist, shall no longer be outstanding, and shall be converted into the right to receive the Offer Price.

Following consummation of the Merger, the Shares will be delisted and will cease to trade on the Nasdaq Stock Market. The Parent and the Purchaser intend to take steps to cause the termination of the registration of the Shares under the Exchange Act and the suspension of all of the Company’s reporting obligations under the Exchange Act as promptly as practicable.”

https://www.sec.gov/Archives/edgar/data/1571498/000119312522219366/d392613dsc14d9a.htm
👍️0
Pt3 Pt3 2 년 전
Thank
👍️0
JJL JJL 2 년 전
1.45 + 1 = 2.45 Is what I read. Absolutely crazy volume today!! I'm very puzzled. This morning I didn't get a chance to read it that good but I would say potentially it should be a $2 trade easily? If I didn't think they were going to buy all the shares I would say it's going to go a lot higher? Like $5 at least. Jmo
👍️0
Pt3 Pt3 2 년 전
Jump in blindly what is this buyout 1.45 so is my share be ok or loss
👍️0
JJL JJL 2 년 전
Retrace
👍️0
Pt3 Pt3 2 년 전
Ready for what
👍️0
JJL JJL 2 년 전
Nice!
👍️0
JJL JJL 2 년 전
I'm ready!!
👍️0
Invest-in-America Invest-in-America 2 년 전
EPZM: See ya-all up on the MOON by NY lunchtime, Peeps!!!!

https://pulse2.com/epizyme-epzm-stock-why-it-surged-over-50-today/

👍️0
Vincent1974 Vincent1974 2 년 전
I have average of 0,59
👍️0
JJL JJL 2 년 전
Am I the only one on ihub that loaded up on this? I guess whatever let her run!!!! My gut says this is going over $5. Since my average is 50 cents I damn sure hope I'm right!!
👍️0
JJL JJL 2 년 전
It hasn't stopped moving up for sure!!!
👍️0
SONARSTOCKZ SONARSTOCKZ 2 년 전
$EPZM Bottom channel breakout attempt. Increasing momentum. Increasing OBV. RSI 55. Need a green close over 50sma for resistance break
👍️0
JJL JJL 2 년 전
Yes I just go to figure a good exit point. It should be a lot higher though!! I hope a 10 bag from here. I mean I thought the news a few days ago was good! Seems most cancer patients had good results from their treatment.
👍️0
Engle1488 Engle1488 2 년 전
Primed and ready for a big run
👍️0
JJL JJL 2 년 전
I completely agree! I loaded!
👍️0
Engle1488 Engle1488 2 년 전
Looking very good last few sessions
👍️0
JJL JJL 2 년 전
When the form fours stop this is going over a dollar
👍️0
JJL JJL 2 년 전
I added. Good news!
👍️0
JJL JJL 3 년 전
Okay, so 7.50 support back then tells me .78 is a screaming buy?? What do I know?
👍️0
Yordle Yordle 3 년 전
I'm 3 grand in @1.53 and holding on for dear life.
👍️0
choo choo trader choo choo trader 3 년 전
Is anybody out there still following this ticker? It looks like an insider recently bought 22M shares.
👍️0
Txguy_01 Txguy_01 5 년 전
Hope it does something tomorrow
👍️0
JC$ JC$ 5 년 전
You'd think it's a no brainer. Usually stocks jump on approval... I guess you just have to get through the sell on news/anticipation crowd first.
👍️0
Txguy_01 Txguy_01 5 년 전
Where is this one going tomorrow?
👍️0
HeadHunter HeadHunter 5 년 전
Nice comeback!
👍️0
jonny_red jonny_red 5 년 전
3 Healthcare Stocks to Watch With Huge FDA Decisions in January.

$DRRX $AIMT $EPZM

https://www.transparenttradersblackbox.com/post/3-healthcare-stocks-to-watch-with-huge-fda-decisions-in-january-drrx-aimt-epzm

👍️0
ClayTrader ClayTrader 6 년 전
* * $EPZM Video Chart 01-04-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
crudeoil24 crudeoil24 6 년 전
7.20 > tutes pounding the table buying those 100K blocks.
👍️0
crudeoil24 crudeoil24 6 년 전
7.00 > Epizyme shares are trading higher after the company announced a registration path for Tazemetostate, provided pipeline updates, and stated FY19 guidance."
👍️0
stockguard stockguard 6 년 전
Upgrade for October 2nd, 2018

Epizyme analyst commentary at SunTrust Epizyme price target raised to $25 from $20 at SunTrust. SunTrust analyst Peter Lawson raised his price target on Epizyme to $25 and kept his Buy rating, citing the FDA decision for a partial clinical hold lift on tazemetostat enrollment. The analyst notes that the company has not announced any substantial changes to the trial design or patient population, but rather will increase patient monitoring after updating its exclusion criteria for new patient enrollment. Lawson contends that the New Drug Application submission for tazemetostat in the treatment of epithelioid sarcoma expected in the first half of 2019 remains on track.
👍️0
stockguard stockguard 6 년 전
Epizyme: An Updated Investment Thesis
Sep. 26, 2018 4:45 PM ET

https://seekingalpha.com/article/4208450-epizyme-updated-investment-thesis
👍️0
floored floored 7 년 전
Rumors of a buyout with the favorable clinical trials being announced. Let's face it, this has a ways to go before gains of any longevity can occur and just when it looks possible, the company is bought out. Nice investment with a 12 to 16 month timeline. EPZM
👍️0
floWteiuQ floWteiuQ 8 년 전
Nice EPZM mention here

http://medicalxpress.com/news/2016-09-prospect-shorter-treatment-chronic-myelogenous.htmlice Epizyme mention here:

👍️0
Yo-Yo Yo-Yo 8 년 전
Looks pretty good over here, may have to play a few shares GLTA !!!
👍️0
floWteiuQ floWteiuQ 8 년 전
You bet your bippy it is!
👍️0
trendmkr trendmkr 8 년 전
Is the Epizyme Dip A Discount Entry Opportunity? http://marketexclusive.com/eyes-epizyme-inc-nasdaqepzm-phase-ii-readout/24197/?icd1
👍️0
BettingAngles BettingAngles 8 년 전
EPZM-Looking to make some traction today..
👍️0
BettingAngles BettingAngles 8 년 전
EPZM-Bouncing
👍️0
MakinBank MakinBank 8 년 전
by who? What do you guys think the pps will if Phase 2 news is good?
👍️0
floWteiuQ floWteiuQ 9 년 전
I think their technology looks promising; therefore, I'm contemplating a small stake, besides bouncing in and out with trading shares.
👍️0
fl89808 fl89808 9 년 전
Price target $32.14!
👍️0
sumotrader sumotrader 9 년 전
Watching EPZM. 60% of the float is short, HUGE insider buys this week.
👍️0
BettingAngles BettingAngles 9 년 전
Year of Biotech's 2016..
👍️0
BettingAngles BettingAngles 9 년 전
http://www.intercooleronline.com/stocks/zacks-investment-research-upgrades-epizyme-inc-epzm-to-buy/327999/
👍️0
BettingAngles BettingAngles 9 년 전
BOUNCE TIME-Part II..
👍️0
BettingAngles BettingAngles 9 년 전
BOUNCE TIME..
👍️0
stocktrademan stocktrademan 9 년 전
$EPZM recent news/filings

bullish

## source: finance.yahoo.com

Mon, 29 Jun 2015 20:44:05 GMT ~ Epizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat (EPZ-6438) at the European Cancer Congress

[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from ...

read full: http://www.noodls.com/view/358420E410FAD6205FD8D7E66BF844A85A90B728
*********************************************************

Mon, 29 Jun 2015 20:34:00 GMT ~ Epizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat (EPZ-6438) at the European Cancer Congress

[Business Wire] - Epizyme, Inc. , a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the phase 1 portion of its ongoing phase 1/2 study of tazemetostat will be presented during the European Cancer Congress 2015, hosted by the European Society of Medical Oncology , to be held in Vienna, Austria, September 25-28, 2015.

read full: http://finance.yahoo.com/news/epizyme-present-clinical-data-ongoing-203400879.html
*********************************************************

Thu, 25 Jun 2015 13:30:01 GMT ~ The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases


read full: http://finance.yahoo.com/news/zacks-analyst-blog-highlights-biomarin-133001320.html
*********************************************************

Wed, 24 Jun 2015 12:44:12 GMT ~ Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog


read full: http://finance.yahoo.com/news/biotech-stock-roundup-biomarin-jumps-124412841.html
*********************************************************

Tue, 23 Jun 2015 15:51:20 GMT ~ Tuesday's Mid-Day Movers: Ambarella Retaliates; Sonic, BlackBerry Hit


read full: http://finance.yahoo.com/news/tuesdays-mid-day-movers-ambarella-155120254.html
*********************************************************

$EPZM charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$EPZM company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/EPZM/company-info
Ticker: $EPZM
OTC Market Place: Not Available
CIK code: not found
Company name: Epizyme, Inc.
Incorporated In:

Business Description:

$EPZM share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$EPZM extra dd links

Company name: Epizyme, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=EPZM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=EPZM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=EPZM+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/news - http://finance.yahoo.com/q/h?s=EPZM+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/EPZM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=EPZM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/EPZM
DTCC (dtcc.com): http://search2.dtcc.com/?q=Epizyme%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Epizyme%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Epizyme%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/EPZM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=EPZM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=EPZM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=EPZM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=EPZM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=EPZM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=EPZM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=EPZM+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/EPZM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=EPZM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/EPZM.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=EPZM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/EPZM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/EPZM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/EPZM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=EPZM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=EPZM



$EPZM DD Notes ~ http://www.ddnotesmaker.com/EPZM
👍️0
investorsito investorsito 9 년 전
The dumping has begun
👍️0
investorsito investorsito 9 년 전
Major correction coming. Shorts will make a killing here
👍️0

최근 히스토리

Delayed Upgrade Clock